Lilly’s Retatrutide Reduces A1C and Weight in Phase 3 Diabetes Trial
Eli Lilly and Company recently announced positive results from the TRANSCEND-T2D-1 trial, a Phase 3 study assessing retatrutide, a groundbreaking medication for type 2 diabetes. This investigational drug is a triple hormone receptor agonist that targets glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.
Key Findings from the TRANSCEND-T2D-1 Trial
The trial included 537 adult participants with type 2 diabetes who struggled to achieve adequate glycemic control through diet and exercise alone. The average duration of diabetes among participants was 2.5 years.
Primary Endpoint Achievements
- Retatrutide achieved an average A1C reduction of up to 2.0% at 40 weeks.
- Placebo participants saw an average A1C reduction of only 0.8%.
- Weight loss was significant, with retatrutide users losing up to 36.6 lbs (16.8%).
The results indicated no plateau in weight loss for those taking retatrutide, suggesting consistent efficacy throughout the treatment period.
Secondary Endpoints
In addition to impressive A1C reductions and weight loss, retatrutide demonstrated clinically meaningful improvements in cardiovascular risk factors. Participants showed reductions in:
- Non-HDL cholesterol
- Triglycerides
- Systolic blood pressure
Adverse Events and Safety Profile
Common side effects noted during the trial included nausea, diarrhea, and vomiting, primarily occurring during dose escalation. The incidence of these adverse events varied with dosage:
| Medication Dosage | Nausea | Diarrhea | Vomiting |
|---|---|---|---|
| 4 mg | 16.4% | 18.7% | 15.7% |
| 9 mg | 19.5% | 26.3% | 15.0% |
| 12 mg | 26.5% | 22.8% | 17.6% |
| Placebo | 3.7% | 4.5% | 2.2% |
Withdrawal due to adverse events occurred in a small percentage of participants across dosages, with a maximum of 5.1% for the 12 mg dosage.
Future Outlook
Detailed findings from the TRANSCEND-T2D-1 trial are set to be presented at the American Diabetes Association Scientific Sessions in June. Additional results from the ongoing retatrutide program are anticipated over the next year.
This innovative medication represents a promising advancement in the management of type 2 diabetes, highlighting Lilly’s commitment to addressing significant health challenges. Retatrutide’s dual impact on A1C control and weight loss offers hope for better diabetes care and improved quality of life for patients.
